FDA
Trump Taps Pro-Life Physician Heidi Overton to Lead FDA, Setting Up Fight Over Abortion Pill Policy
President Trump announced this week that he is nominating Dr. Heidi Overton, a physician and White House domestic policy aide, to serve as the next commissioner of the Food and Drug Administration — a pick that instantly reignited the long-running national fight over access to the abortion drug mifepristone and drew sharp opposition from Democratic senators before her confirmation process has even begun. Who Is Heidi Overton Overton currently serves as a deputy assistant to the president for domestic policy, a role in which The Atlantic has described her as one of the most influential public health officials in Trump’s second term, regularly briefing the president directly on health matters. Before joining the White House, she served as vice chair and chief policy officer at the America First Policy Institute, a conservative think tank closely aligned with the administration’s broader agenda. If confirmed by the Senate, she would replace Dr. Marty Makary, who resigned from the position in May following friction with the White House over issues including vaping regulation and abortion pill access. Trump’s Case for Her Announcing the pick on Truth Social, Trump was effusive in his praise, calling Overton a “rockstar” who is “smart and respected by all” and describing her as central to what he called the most transformative health agenda in American history. “She is known to take on the hardest issues, and bring me solutions that work best for the country,” Trump wrote, adding that Overton would work closely with Health Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz to advance his priorities, including faster drug approvals — a goal the pharmaceutical industry has long pushed for — and continued progress on Kennedy’s “Make America Healthy Again” agenda. A Long, Public Record on Abortion Overton’s nomination has drawn intense attention primarily because of her extensive public record opposing abortion. After the Supreme Court’s 2022 decision overturning Roe v. Wade, Overton celebrated the ruling as a “huge victory for life,” saying it would “allow Americans to reevaluate the value of the potential of every baby in the womb and choose life through a democratic process.” She has separately advocated for Congress to place strict limits on mifepristone and misoprostol, the two drugs most commonly used in medication abortions, arguing such restrictions are necessary “to protect women and children.” That record matters significantly for the position she’s been nominated to fill: the FDA is currently in the midst of an ongoing safety review of mifepristone, a drug first approved by the agency in 2000 and later authorized for mail-order dispensing under a Biden-era policy. Whoever leads the FDA will have substantial influence over how — and whether — that review affects the drug’s availability nationwide. Democrats Signal Fierce Opposition Senate Democrats wasted no time announcing their opposition. Sen. Patty Murray of Washington, a member of the committee that will consider Overton’s nomination, didn’t mince words. “Heidi Overton is a far-right, anti-abortion extremist who has no business leading the FDA,” Murray said in a statement. “The American people deserve someone who will put science and facts FIRST, not another Trump sycophant who will make it their mission to attack medication abortion. I will vote NO.” Reproductive rights organizations echoed that opposition. Mini Timmaraju, president and CEO of Reproductive Freedom for All, argued the nomination reflects a broader strategy by the administration. “Donald Trump is trying to put an anti-abortion extremist in charge of any agency that could seriously undermine reproductive healthcare — including the agency that could roll back access to mifepristone nationwide,” Timmaraju said, adding that Overton’s nomination represents “another alarming step in Trump’s plan to weaponize every part of the federal government to restrict abortion nationwide.” Even Some Republicans Have Concerns Notably, opposition to the pick hasn’t been confined strictly to Democrats. Sen. Bill Cassidy of Louisiana, the Republican chairman of the Senate Health, Education, Labor, and Pensions Committee that will oversee Overton’s confirmation hearing, raised his own reservations — though his concerns centered on managerial experience rather than her policy positions. “While I respect Dr. Overton’s experience as a physician, I have strong concerns about her nomination to be FDA commissioner,” Cassidy wrote on X. “Her lack of managerial experience does not prepare her well for leading a large organization that is already struggling with turnover and low morale.” A Balancing Act Ahead Whoever ultimately leads the FDA under the current administration faces competing pressures that have already proven difficult to navigate. Kennedy has pushed the agency toward looser restrictions on certain unproven peptide treatments, anti-abortion lawmakers and advocacy groups are pressing hard for tighter restrictions on mifepristone, and Trump himself has pushed the agency to approve flavored e-cigarette products for the first time — a move public health advocates worry could fuel renewed teenage vaping. Overton’s predecessor, Makary, ultimately resigned amid friction generated by exactly this kind of competing pressure, leaving several major policy questions — including the future of ultraprocessed food regulation, antidepressant labeling, and COVID-19 vaccine guidance — unresolved when he departed in May. Supporters See a Needed Course Correction Backers of the nomination argue that after a series of FDA leaders who drew criticism from anti-abortion advocates and industry alike for insufficient decisiveness, Overton represents a clear, values-aligned choice who will finally give the administration’s health priorities a fully committed advocate at the top of the agency. From this perspective, her extensive policy background and closeness to the White House’s broader health agenda — rather than being liabilities — position her to implement reforms more effectively than a commissioner operating at arm’s length from the administration’s core priorities. What Happens Next Overton’s nomination will need to clear the Senate HELP Committee, where Republicans hold a narrow one-seat majority, before advancing to a full Senate floor vote. Given both the unified Democratic opposition already on display and Cassidy’s own stated reservations as the committee’s Republican chairman, her path to confirmation — while still likely given the overall Republican Senate majority — is not guaranteed to be smooth. A confirmation…
FDA Approves First-Ever mRNA Flu Vaccine After Reversing Its Own Earlier Rejection
The FDA approved Moderna’s mRNA-based flu vaccine this week, clearing the way for the first influenza shot built on the same technology used in COVID-19 vaccines — a regulatory turnaround that seemed unlikely just six months ago, after the agency initially refused to even review the product. What Got Approved The vaccine, branded mFlusiva, received standard FDA approval for adults ages 50 to 64 and accelerated approval for adults 65 and older, with the latter approval contingent on Moderna completing an additional postmarketing study to confirm clinical benefit in that higher-risk age group. In a late-stage clinical trial involving more than 40,000 participants, mFlusiva demonstrated roughly 27% greater effectiveness against influenza-like illness compared to a standard-dose flu vaccine — a meaningful edge for a population that faces disproportionately severe complications, including pneumonia, from seasonal flu. Moderna CEO Stéphane Bancel called the approval a milestone for the company’s broader platform. “Flu remains a significant public health challenge, and mFLUSIVA provides an important new option for America’s seniors,” Bancel said in a statement, adding that the approval “reflects the ongoing potential of our mRNA platform to help address important public health challenges through continued scientific innovation.” A Bumpy Road to Approval The path here wasn’t straightforward. Back in February, then-FDA biologics chief Vinay Prasad issued a rare “refusal-to-file” notice, overturning career staff’s recommendation and declining to even review the vaccine based on the data package Moderna had submitted — a decision some observers speculated may have been influenced by broader skepticism toward mRNA technology within the administration. Just two weeks later, after Moderna publicly disclosed both the rejection and its own frustration with the decision, the FDA reversed course and agreed to move forward with a review in time for the 2026-2027 flu season. Prasad left the FDA at the end of April. Once under formal review, the vaccine’s data made a strong impression: the FDA’s outside advisory panel, the Vaccines and Related Biological Products Advisory Committee, voted unanimously in June to recommend approval. One panelist, Dr. Flor Munoz-Rivas of Baylor College of Medicine, praised the rigor of the underlying research. “The studies that were presented today were very well conducted,” she said. “They have very clear results that are very robust.” An Unusual Recommendation Landscape Vaccines are typically formally endorsed by the CDC’s Advisory Committee on Immunization Practices before widespread use and insurance coverage kick in — but that panel has been unable to meet due to an ongoing federal court dispute over its composition and authority. Absent a green light from that committee, the vaccine can still legally be prescribed, but how quickly it gets folded into standard recommendations, and whether insurers move to cover it without that formal endorsement, remains an open question that could shape how widely it’s actually used this fall. The Bigger Picture for mRNA Technology Supporters of the technology argue this approval matters well beyond flu season alone. Because mRNA vaccines can be manufactured and updated far more quickly than traditional egg-based flu vaccines, proponents say the platform gives the country a meaningful head start in responding to fast-mutating flu strains or, in a worst-case scenario, a future pandemic strain — since formulations can be adjusted on a compressed timeline compared to conventional manufacturing. The approval also arrives at a moment when mRNA vaccine technology has faced real skepticism in Washington, with the administration’s broader health leadership having voiced public doubts about the platform in the past. That the FDA ultimately reversed its own initial rejection, following unanimous support from an independent scientific advisory panel, suggests the agency’s career scientific review process held up even amid political headwinds — a point advocates for regulatory independence are likely to highlight going forward. No new or unexpected safety signals emerged during the review; reported side effects, including fatigue, joint pain, and injection-site discomfort, were consistent with what’s typically seen with other mRNA vaccines already on the market. Moderna says it expects mFlusiva to begin reaching select retailers within a few weeks, ahead of the upcoming flu season, with regulatory reviews also underway in the European Union, Canada, and Australia. This story is developing.